Abstract
Several molecular and genetic studies have provided new perspectives on the histologic classification of bladder tumors. Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer. All these changes are behind the use of non-traditional approach to therapy of bladder cancer patients and are ready to change our daily practice of uro-oncology. The observed correlation of some molecular alterations with tumor behavior and the identification of their targets at cellular level might support the use of molecular changes together with morphological data to develop new clinical and biological strategies to manage patients with urothelial cancer. The current review provides comprehensive data to support personalized therapy for bladder cancer based on an integrated approach including pathologic and clinical features and molecular biology.
Keywords: Bladder cancer, genito-urinary cancers, molecular pathology, personalized therapy, precision oncology, targeted therapy.
Current Drug Targets
Title:Bladder Cancer: Molecular Determinants of Personalized Therapy
Volume: 16 Issue: 2
Author(s): Antonio Lopez-Beltran, Matteo Santoni, Francesco Massari, Chiara Ciccarese, Giampaolo Tortora, Liang Cheng, Holger Moch, Marina Scarpelli, Carlos Reymundo and Rodolfo Montironi
Affiliation:
Keywords: Bladder cancer, genito-urinary cancers, molecular pathology, personalized therapy, precision oncology, targeted therapy.
Abstract: Several molecular and genetic studies have provided new perspectives on the histologic classification of bladder tumors. Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer. All these changes are behind the use of non-traditional approach to therapy of bladder cancer patients and are ready to change our daily practice of uro-oncology. The observed correlation of some molecular alterations with tumor behavior and the identification of their targets at cellular level might support the use of molecular changes together with morphological data to develop new clinical and biological strategies to manage patients with urothelial cancer. The current review provides comprehensive data to support personalized therapy for bladder cancer based on an integrated approach including pathologic and clinical features and molecular biology.
Export Options
About this article
Cite this article as:
Lopez-Beltran Antonio, Santoni Matteo, Massari Francesco, Ciccarese Chiara, Tortora Giampaolo, Cheng Liang, Moch Holger, Scarpelli Marina, Reymundo Carlos and Montironi Rodolfo, Bladder Cancer: Molecular Determinants of Personalized Therapy, Current Drug Targets 2015; 16 (2) . https://dx.doi.org/10.2174/1389450116666150204115756
DOI https://dx.doi.org/10.2174/1389450116666150204115756 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Expression Profiles and Bioinformatics Analysis of Full-length circRNA Isoforms in Gliomas
Current Bioinformatics P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets Positron Emission Tomography Radiopharmaceuticals for Sex Steroid Hormone Receptor Imaging
Current Medicinal Chemistry Aberrant DNA Methylation and Prostate Cancer
Current Genomics Molecular and Cellular Mechanisms of Hexavalent Chromium-Induced Lung Cancer: An Updated Perspective
Current Drug Metabolism Overview of Systems Biology and Omics Technologies
Current Medicinal Chemistry Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Electrically-Assisted Nucleic Acids Delivery to Tissues In Vivo: Where Do We Stand?
Current Pharmaceutical Design Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Recent Development of Copolymeric Delivery System for Anticancer Agents Based on Cyclodextrin Derivatives
Anti-Cancer Agents in Medicinal Chemistry Advantages of Multidetector CT Cystoscopy in the Detection of Bladder Tumors
Current Medical Imaging Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Advances in Targeting Insulin-like Growth Factor Signaling Pathway in Cancer Treatment
Current Pharmaceutical Design Synthesis and Biological Evaluation of Scutellaria Flavone Cyclaneaminol Mannich Base Derivatives as Novel CDK1 Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Management of Fallopian Tube Cancer
Reviews on Recent Clinical Trials (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Mammalian Nucleoside Transporters
Current Drug Metabolism Advances in Hyaluronic Acid-Based Drug Delivery Systems
Current Drug Targets Dietary Phytochemicals in Cancer Signalling Pathways: Role of miRNA Targeting
Current Medicinal Chemistry Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design